Global Somatostatin Analogs Market Growth 2023-2029

Global Somatostatin Analogs Market Growth 2023-2029

Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.

LPI (LP Information)' newest research report, the “Somatostatin Analogs Industry Forecast” looks at past sales and reviews total world Somatostatin Analogs sales in 2022, providing a comprehensive analysis by region and market sector of projected Somatostatin Analogs sales for 2023 through 2029. With Somatostatin Analogs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Somatostatin Analogs industry.

This Insight Report provides a comprehensive analysis of the global Somatostatin Analogs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Somatostatin Analogs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Somatostatin Analogs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Somatostatin Analogs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Somatostatin Analogs.

The global Somatostatin Analogs market size is projected to grow from US$ 4402.4 million in 2022 to US$ 6272.2 million in 2029; it is expected to grow at a CAGR of 6272.2 from 2023 to 2029.

Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Somatostatin Analogs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Octreotide
Lanreotide
Pasireotide

Segmentation by application
Acromegaly
Carcinoid Syndrome
Neuroendocrine Tumor
Cushing Syndrome
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Peptron
Chiasma
Ipsen Biopharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Somatostatin Analogs market?

What factors are driving Somatostatin Analogs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Somatostatin Analogs market opportunities vary by end market size?

How does Somatostatin Analogs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.